company background image
ICLR

ICONNasdaqGS:ICLR Stock Report

Market Cap

US$22.2b

7D

0.3%

1Y

36.1%

Updated

03 Dec, 2021

Data

Company Financials +
ICLR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health2/6
Dividends0/6

ICLR Stock Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

ICON Competitors

IQVIA Holdings

NYSE:IQV

US$50.0b

Avantor

NYSE:AVTR

US$23.3b

Charles River Laboratories International

NYSE:CRL

US$18.0b

PPD

NasdaqGS:PPD

US$16.6b

Price History & Performance

Summary of all time highs, changes and price drops for ICON
Historical stock prices
Current Share PriceUS$272.81
52 Week HighUS$301.72
52 Week LowUS$168.76
Beta0.84
1 Month Change-1.01%
3 Month Change3.98%
1 Year Change36.07%
3 Year Change95.38%
5 Year Change256.94%
Change since IPO4,189.80%

Recent News & Updates

Oct 31
Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?

Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?

Let's talk about the popular ICON Public Limited Company ( NASDAQ:ICLR ). The company's shares saw a significant share...

Oct 16
ICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet

ICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Oct 01
Estimating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Estimating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

In this article we are going to estimate the intrinsic value of ICON Public Limited Company ( NASDAQ:ICLR ) by taking...

Aug 26

ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research

ICON Public Limited Company is a leading clinical research organization, aiding researchers and companies across the entire industry in performing their work. The healthcare industry is extremely strong at the moment and set to see favorable tailwinds over the next few years. I believe ICON has been shrewd in its management and growth so far and is a low-risk investment for any investor.

Shareholder Returns

ICLRUS Life SciencesUS Market
7D0.3%-2.7%-2.7%
1Y36.1%29.2%16.6%

Return vs Industry: ICLR exceeded the US Life Sciences industry which returned 31.6% over the past year.

Return vs Market: ICLR exceeded the US Market which returned 19.4% over the past year.

Price Volatility

Is ICLR's price volatile compared to industry and market?
ICLR volatility
ICLR Average Weekly Movement3.7%
Life Sciences Industry Average Movement7.9%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: ICLR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ICLR's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199037,960Steve Cutlerhttps://www.iconplc.com

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services.

ICON Fundamentals Summary

How do ICON's earnings and revenue compare to its market cap?
ICLR fundamental statistics
Market CapUS$22.21b
Earnings (TTM)US$177.95m
Revenue (TTM)US$4.36b

124.8x

P/E Ratio

5.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ICLR income statement (TTM)
RevenueUS$4.36b
Cost of RevenueUS$3.15b
Gross ProfitUS$1.21b
ExpensesUS$1.03b
EarningsUS$177.95m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.19
Gross Margin27.72%
Net Profit Margin4.09%
Debt/Equity Ratio74.4%

How did ICLR perform over the long term?

See historical performance and comparison

Valuation

Is ICON undervalued compared to its fair value and its price relative to the market?

1.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ICLR ($272.81) is trading below our estimate of fair value ($276.43)

Significantly Below Fair Value: ICLR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ICLR is poor value based on its PE Ratio (124.8x) compared to the US Life Sciences industry average (44x).

PE vs Market: ICLR is poor value based on its PE Ratio (124.8x) compared to the US market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: ICLR is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: ICLR is good value based on its PB Ratio (2.8x) compared to the US Life Sciences industry average (4.6x).


Future Growth

How is ICON forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

33.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICLR's forecast earnings growth (33.7% per year) is above the savings rate (2%).

Earnings vs Market: ICLR's earnings (33.7% per year) are forecast to grow faster than the US market (14.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ICLR's revenue (17.2% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ICLR's revenue (17.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ICLR's Return on Equity is forecast to be low in 3 years time (12.1%).


Past Performance

How has ICON performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ICLR has a large one-off loss of $115.1M impacting its September 30 2021 financial results.

Growing Profit Margin: ICLR's current net profit margins (4.1%) are lower than last year (11.6%).


Past Earnings Growth Analysis

Earnings Trend: ICLR's earnings have grown by 3.7% per year over the past 5 years.

Accelerating Growth: ICLR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ICLR had negative earnings growth (-44.7%) over the past year, making it difficult to compare to the Life Sciences industry average (72.2%).


Return on Equity

High ROE: ICLR's Return on Equity (2.2%) is considered low.


Financial Health

How is ICON's financial position?


Financial Position Analysis

Short Term Liabilities: ICLR's short term assets ($3.1B) exceed its short term liabilities ($2.3B).

Long Term Liabilities: ICLR's short term assets ($3.1B) do not cover its long term liabilities ($7.4B).


Debt to Equity History and Analysis

Debt Level: ICLR's net debt to equity ratio (61.7%) is considered high.

Reducing Debt: ICLR's debt to equity ratio has increased from 40.4% to 74.4% over the past 5 years.

Debt Coverage: ICLR's debt is not well covered by operating cash flow (12.4%).

Interest Coverage: ICLR's interest payments on its debt are well covered by EBIT (3.5x coverage).


Balance Sheet


Dividend

What is ICON current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICLR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICLR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICLR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ICLR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Steve Cutler (61 yo)

4.75yrs

Tenure

US$8,302,000

Compensation

Dr. Steven A. Cutler, also known as Steve, Ph D., MBA, has been the Chief Executive Officer of ICON Public Limited Company since March 01, 2017. Dr. Cutler is the Chief Operating Officer of ICON at ICON Cl...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD8.30M) is about average for companies of similar size in the US market ($USD11.16M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ICLR's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: ICLR's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.2%.


Top Shareholders

Company Information

ICON Public Limited Company's employee growth, exchange listings and data sources


Key Information

  • Name: ICON Public Limited Company
  • Ticker: ICLR
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$22.206b
  • Shares outstanding: 81.40m
  • Website: https://www.iconplc.com

Number of Employees


Location

  • ICON Public Limited Company
  • South County Business Park
  • Leopardstown
  • Dublin
  • Co. Dublin
  • 18
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/03 23:57
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.